Duke University, Durham, NC, USA.
RTI Health Solutions, Belfast, UK.
Patient. 2021 Nov;14(6):827-836. doi: 10.1007/s40271-021-00518-y. Epub 2021 May 7.
Discrete-choice experiments (DCEs) are increasingly conducted to quantify risk tolerance by computing maximum acceptable risk (MAR) for improvements in efficacy or other benefits gained from new medical treatments. To compute MARs from DCE data, respondents are asked to make choices under uncertainty between treatments. Specific treatment-related harms are included in the choice questions as probabilistic adverse events (AEs), and choice variation with the probability of these outcomes is assumed to indicate their effect on the expected utility of treatments. With a limited number of comparisons between profiles, calculation of MARs requires understanding how outcome probabilities that are not explicitly considered in the DCE can change the value of medical technologies. This study aims to examine how various assumptions on the expected disutility of these excluded probabilities can result in different MAR measures.
We summarize commonly used empirical specifications for the expected disutility of AEs and derive the resulting MAR functions. We then discuss an empirical application on treatments to delay bone metastases in oncology patients with solid tumors.
A total of 187 respondents completed the DCE. Results show the impact of making various assumptions about the expected disutility of AEs, and the resulting MAR values for specific health benefits. As expected, different assumptions resulted in variations in MAR values for specific health benefits. Even with small differences in MAR measures, our results suggest that the assumptions evaluated here can lead to different conclusions about the acceptability of a medical technology.
Results show possible systematic variations in MARs caused by the assumed form of the effect of changes in the probability of AEs. Furthermore, we find that different assumptions can lead to different conclusions about the acceptability of a medical technology, even when MAR distributions overlap. This result suggests that researchers should evaluate the assumptions they are making for these effects and use sensitivity analysis to evaluate the robustness of risk-tolerance measures from stated-preference data.
离散选择实验(DCE)越来越多地被用来通过计算新医疗治疗的疗效或其他收益提高的最大可接受风险(MAR)来量化风险容忍度。为了从 DCE 数据中计算 MAR,要求受访者在治疗之间的不确定性下做出选择。特定的与治疗相关的危害被包含在选择问题中作为概率不良事件(AE),并且对这些结果的概率的选择变化被认为指示了它们对治疗的预期效用的影响。由于在概况之间进行的比较数量有限,MAR 的计算需要理解在 DCE 中未明确考虑的结果概率如何改变医疗技术的价值。本研究旨在研究对这些排除概率的预期不便利性的各种假设如何导致不同的 MAR 度量。
我们总结了常用的 AE 预期不便利性的经验规格,并推导出由此产生的 MAR 函数。然后,我们讨论了一个关于治疗延迟实体瘤患者骨转移的应用实例。
共有 187 名受访者完成了 DCE。结果表明,对 AE 预期不便利性的各种假设的影响,以及对特定健康益处的 MAR 值。正如预期的那样,不同的假设导致了特定健康益处的 MAR 值的变化。即使 MAR 度量值存在微小差异,我们的结果表明,这里评估的假设可以导致对医疗技术可接受性的不同结论。
结果表明,由于 AE 概率变化的影响的假设形式,MAR 可能会出现系统变化。此外,我们发现,即使 MAR 分布重叠,不同的假设也可能导致对医疗技术的可接受性的不同结论。该结果表明,研究人员应该评估他们对这些影响的假设,并使用敏感性分析来评估来自陈述偏好数据的风险容忍度措施的稳健性。